Sort   by:  
 Page size 
ProteomicsGenome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Hypomethylating agents (HMAs) are frontline therapies effective at altering the natural course of Myelodysplastic Neoplasms (MDS). However, acquired resistance and treatment failure are hallmarks of HMA therapy. Developing effective and rational HMA-focused combinatorial therapies is challenging as...
ORGANISM(S): Homo sapiens (Human) 
2024-07-25 | PXD050539 | Pride
Myelodysplastic neoplasms Proteomics Genome-wide crispr-cas9 screen Sumo 
GenomicsDNA hypomethylating agents increase activation and cytolytic activity of CD8+ T-cells
DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T-cells
PRJNA637641 | ENA
GenomicsDNA hypomethylating agents increase activation and cytolytic activity of CD8+ T-cells
DNA hypomethylating agents (HMAs) induce Type I/III interferon signaling through dsRNA-mediated viral mimicry in cancer cells. Yet, the direct effects of HMAs in immune cells remains less clear. Here, we demonstrate that HMA treatments can directly modulate the anti-tumor response and effector funct...
ORGANISM(S): Homo sapiens 
2021-02-08 | GSE151917 | GEO
UnknownMechanisms of Action of Hypomethylating Agents: Endogenous Retroelements at the Epicenter.
Not available
S-EPMC7985079 | biostudies-literature
OtherGenome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia (Screen)
Hypomethylating agents (HMAs) are frontline therapies effective at altering the natural course of Myelodysplastic Neoplasms (MDS). However, acquired resistance and treatment failure are hallmarks of HMA therapy. Developing effective and rational HMA-focused combinatorial therapies is challenging as ...
ORGANISM(S): Homo sapiens 
2024-07-24 | GSE261338 | GEO
OtherGenome-wide CRISPR/Cas9 library screening identified OGDH as a regulator of disease progress and HMAs-resistance in MDS by reprogramming glutamine metabolism
Resistance of hypomethylating agents (HMAs) remains a challenge in myelodysplastic neoplasms (MDS), leading to a poor prognosis. Altered metabolism is also reported to be closely associated with drug resistance in hematological malignancies. Here, we conducted a genome-wide CRISPR/Cas9 library scree...
ORGANISM(S): Homo sapiens 
2024-08-05 | GSE273914 | GEO
TranscriptomicsGenome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and SUMOylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia (RNA-Seq)
Hypomethylating agents (HMAs) are frontline therapies effective at altering the natural course of Myelodysplastic Neoplasms (MDS). However, acquired resistance and treatment failure are hallmarks of HMA therapy. Developing effective and rational HMA-focused combinatorial therapies is challenging as ...
ORGANISM(S): Homo sapiens 
2024-07-24 | GSE261337 | GEO
UnknownHypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Not available
S-EPMC7947882 | biostudies-literature
UnknownInhibition of TOPORS ubiquitin ligase augments the efficacy of DNA hypomethylating agents through DNMT1 stabilization.
Not available
S-EPMC11358161 | biostudies-literature
UnknownClinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.
Not available
S-EPMC8678301 | biostudies-literature
Sort   by:  
 Page size